Cargando…

Rationale, design, demographics and baseline characteristics of the randomized, controlled, Phase 2b SAPPHIRE study of verinurad plus allopurinol in patients with chronic kidney disease and hyperuricaemia

BACKGROUND: Verinurad is a human uric acid (UA) transporter (URAT1) inhibitor known to decrease serum UA (sUA) levels and that may reduce albuminuria. In a Phase 2a study (NCT03118739), treatment with verinurad + febuxostat lowered urine albumin-to-creatinine ratio (UACR) at 12 weeks by 39% (90% con...

Descripción completa

Detalles Bibliográficos
Autores principales:	Heerspink, Hiddo J L, Stack, Austin G, Terkeltaub, Robert, Greene, Tom A, Inker, Lesley A, Bjursell, Magnus, Perl, Shira, Rikte, Tord, Erlandsson, Fredrik, Perkovic, Vlado
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9317164/ https://www.ncbi.nlm.nih.gov/pubmed/34383954 http://dx.doi.org/10.1093/ndt/gfab237

Ejemplares similares

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants
por: Johansson, Susanne, et al.
Publicado: (2022)

Hyperuricaemia, gout and allopurinol in the CKD Queensland registry
por: Jeyaruban, A., et al.
Publicado: (2021)

Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study
por: Shiramoto, Masanari, et al.
Publicado: (2018)

Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study
por: Stack, Austin G, et al.
Publicado: (2020)

New clinical trial designs for establishing drug efficacy and safety in a precision medicine era
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Multiple Dose Administration of Verinurad (RDEA3170) and Allopurinol in Adult Male Subjects With Gout
por: Kankam, Martin, et al.
Publicado: (2018)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with allopurinol in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia
por: MacDonald, Thomas M, et al.
Publicado: (2014)

The Management of Hyperuricaemia
por: Bayliss, Richard, et al.
Publicado: (1984)

Impact of random variation in albuminuria and estimated glomerular filtration rate on patient enrolment and duration of clinical trials in nephrology
por: Waijer, Simke W., et al.
Publicado: (2022)

Pharmacokinetics, Pharmacodynamics, and Tolerability of Concomitant Administration of Verinurad and Febuxostat in Healthy Male Volunteers
por: Hall, Jesse, et al.
Publicado: (2018)

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) common language definition of gout
por: Murdoch, Rachel, et al.
Publicado: (2021)

Favipiravir: Hyperuricaemia: case report
Publicado: (2021)

Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy
por: Heerspink, Hiddo J. L., et al.
Publicado: (2018)

Advances in the management of malignancy-associated hyperuricaemia.
por: Mahmoud, H. H., et al.
Publicado: (1998)

Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor
por: Smith, William B., et al.
Publicado: (2018)

Discovery and characterization of verinurad, a potent and specific inhibitor of URAT1 for the treatment of hyperuricemia and gout
por: Tan, Philip K., et al.
Publicado: (2017)

Temporal trends in hyperuricaemia in the Irish health system from 2006-2014: A cohort study
por: Kumar A. U., Arun, et al.
Publicado: (2018)

Initiation of the SGLT2 inhibitor canagliflozin to prevent kidney and heart failure outcomes guided by HbA1c, albuminuria, and predicted risk of kidney failure
por: Tye, Sok Cin, et al.
Publicado: (2022)

Hyperuricaemia and the metabolic syndrome in type 2 DM
por: Ogbera, Anthonia O, et al.
Publicado: (2010)

The first metatarsophalangeal joint in gout and asymptomatic hyperuricaemia
por: Stewart, Sarah, et al.
Publicado: (2015)

Function of Uric Acid Transporters and Their Inhibitors in Hyperuricaemia
por: Sun, Hao-lu, et al.
Publicado: (2021)

Gout and hyperuricaemia: modifiable cardiovascular risk factors?
por: Burnier, Michel
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy adult male subjects
por: Shen, Zancong, et al.
Publicado: (2017)

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial
por: Sen, Taha, et al.
Publicado: (2021)

Treating Early-Stage CKD With New Medication Therapies: Results of a CKD Patient Survey Informing the 2020 NKF-FDA Scientific Workshop on Clinical Trial Considerations for Developing Treatments for Early Stages of Common, Chronic Kidney Diseases
por: Damron, Kelli Collins, et al.
Publicado: (2022)

Incident gout and erectile dysfunction: is hyperuricaemia the elephant in the room?
por: Abhishek, Abhishek, et al.
Publicado: (2017)

Hyperuricaemia in Cardiovascular Diseases: A Passive or an Active Player?
por: Katsiki, Niki, et al.
Publicado: (2015)

Hyperuricaemia: prevalence and association with mortality in an elderly Finnish population
por: Timsans, Janis, et al.
Publicado: (2023)

Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials
por: Heerspink, Hiddo J Lambers, et al.
Publicado: (2009)

Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study
por: Fleischmann, Roy, et al.
Publicado: (2018)

Failure to reach uric acid target of <0.36 mmol/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality
por: Pérez Ruiz, Fernando, et al.
Publicado: (2019)

Short‐Term Changes in Albuminuria and Risk of Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: A Post Hoc Analysis of the EMPA‐REG OUTCOME Trial
por: Waijer, Simke W., et al.
Publicado: (2020)

SAPPHiRE and LHeC
por: Zimmermann, F
Publicado: (2012)

Alterations of the Gut Microbiome Associated With the Treatment of Hyperuricaemia in Male Rats
por: Yu, Yiran, et al.
Publicado: (2018)

Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
por: Bardin, Thomas, et al.
Publicado: (2017)

Asymptomatic hyperuricaemia in chronic kidney disease: mechanisms and clinical implications
por: Anders, Hans-Joachim, et al.
Publicado: (2023)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS
por: Koshino, Akihiko, et al.
Publicado: (2022)

Allopurinol induced erythroderma
por: Sharma, Geeta, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_euumgsng8ncemh5mlnr3kn4r3k